Research use only. Not for use in humans or animals. All products and information on this site are provided strictly for in-vitro laboratory research purposes. They are not for use in humans or animals, and are not drugs, foods, cosmetics, or medical devices.
Retatrutide vs Tirzepatide: A Research Comparison
Retatrutide and tirzepatide are two of the most-studied incretin research peptides, and the single question researchers ask most is how they differ. The short answer: tirzepatide is a dual receptor agonist and retatrutide is a triple receptor agonist. This comparison covers what that means at the receptor level, how each is classified, and how to verify research-grade material. Semaglutide is included as the single-agonist reference point.
Side-by-side
| Semaglutide | Tirzepatide | Retatrutide | |
|---|---|---|---|
| Receptors engaged | GLP-1 | GIP + GLP-1 | GIP + GLP-1 + glucagon |
| Agonist type | Single | Dual | Triple |
| Research designation | — | LY3298176 | LY3437943 |
| Half-life extension | Fatty-acid moiety | Fatty-acid moiety | Long-acting analog |
| Appearance | White powder | White powder | White powder |
Mechanism at the receptor level
- GLP-1 receptor — the shared target of all three. Central to incretin research.
- GIP receptor — added by tirzepatide and retatrutide. Studies compare how adding GIP engagement changes signaling relative to GLP-1 alone.
- Glucagon receptor — added only by retatrutide. This is the defining difference: retatrutide is studied for how simultaneous glucagon-receptor engagement changes energy-metabolism markers in animal models compared with the dual agonist.
What researchers study in the comparison
In laboratory and preclinical research, the retatrutide-vs-tirzepatide comparison focuses on:
- Comparative receptor pharmacology — binding affinity and selectivity across the shared and distinct receptors.
- Energy-metabolism models — how triple-receptor engagement differs from dual in animal models.
- Signaling-pathway characterization — downstream effects of each receptor combination in vitro.
Both peptides offered here are research chemicals for laboratory use only. Not for use in humans or animals.
Which to choose for a study
The choice is dictated by the research question, not by any ranking of the peptides:
- Studying dual GIP + GLP-1 signaling → tirzepatide.
- Studying triple GIP + GLP-1 + glucagon signaling → retatrutide.
- Needing a single-agonist GLP-1 reference → semaglutide.
For the individual overviews, see what is retatrutide →, tirzepatide research overview →, and semaglutide research overview →.
Both peptides ship as a lyophilized (freeze-dried) powder for laboratory use. ships as a lyophilized (freeze-dried) powder. Researchers refer to the lot-specific COA and their own validated laboratory protocols for handling.
How research-grade material is verified
Every batch from a credible US supplier should arrive with a third-party Certificate of Analysis (COA) for that exact lot. Peptide Technologies publishes a COA on every batch and ties it to a QR code on the vial. A complete COA reports:
- Identity — mass spectrometry (ESI-MS) confirming the observed mass matches the theoretical mass of the target sequence.
- Purity — reverse-phase HPLC, reported as percent peak area at a fixed wavelength (typically 220 nm). Research-grade material is ≥99% by area.
- Net content — gravimetric confirmation the vial holds the stated mass within tolerance.
- Endotoxin — LAL assay below research-grade thresholds.
If a vendor cannot show a lot-specific COA, you cannot verify what is in the vial. Browse the full COA library →
How to source research-grade material
For laboratory research, sourcing quality comes down to a few checks:
- Lot-specific COA from an accredited, independent laboratory — not a generic marketing PDF.
- HPLC purity ≥99% by peak area, with the chromatogram shown.
- US synthesis and finishing, so the chain of custody is documented end to end.
- Cold-chain shipping for lyophilized material, so the product arrives stable.
Peptide Technologies meets each of these and publishes a third-party COA for every lot. Browse the public COA library →
FAQ
What is the difference between retatrutide and tirzepatide?
Tirzepatide is a dual agonist of the GIP and GLP-1 receptors. Retatrutide is a triple agonist that adds glucagon-receptor engagement to the same GIP + GLP-1 activity.
Is retatrutide stronger than tirzepatide?
Research compares them by mechanism, not strength. Retatrutide engages one additional receptor (glucagon); which is appropriate depends entirely on the research question.
Where does semaglutide fit in?
Semaglutide is the single-agonist reference: it engages only the GLP-1 receptor, versus tirzepatide's two and retatrutide's three.
How are these peptides verified?
Research-grade incretin peptides are verified by HPLC for purity, mass spectrometry for identity, and an LAL endotoxin assay, reported on a lot-specific third-party COA.
Are they research chemicals?
Yes. All are research chemicals supplied for laboratory use only. Not for use in humans or animals.